文献速递肾小球疾病遗传性与小管间质肾病

儿童IgA肾病中罕见胶原杂合变异

Rare Collagenous Heterozygote Variants in Children With IgA Nephropathy.
PubMed 文献 · Kidney Int Rep · 2021-03-03

该研究对36例儿童IgA肾病(cIgAN)患者进行COL4A3/A4/A5外显子测序,发现4例携带ACMG 4/5类COL4A3杂合变异(COL4A3-cIgAN)。这些患者对强化免疫抑制治疗反应良好,但似乎更易出现严重IgAN表现,如更多肾小球硬化和eGFR下降。结论提示COL4A3变异不应自动排除免疫抑制方案,且可能有助于cIgAN严重度分层。

要点

  • 儿童IgA肾病患者中可检出ACMG 4/5类COL4A3杂合变异,发生率为4/36。
  • 携带COL4A3变异的cIgAN患者对强化免疫抑制治疗反应良好。
  • COL4A3-cIgAN患者更易出现肾小球硬化和eGFR下降,提示病情更重。

核心结论

  • 儿童IgA肾病伴COL4A3致病性杂合变异时,应考虑严重发作的易感因素。
  • COL4A3变异不应自动排除cIgAN的免疫抑制治疗。
  • 早期cIgAN检出ACMG 4/5类COL4A3变异可能有助于在牛津分类之外进行严重度分层。

研究设计与样本

  • 对36例儿童IgA肾病患者进行COL4A3、COL4A4和COL4A5外显子测序,并回顾性收集临床资料和治疗。
  • COL4A3/A4/A5变异按ACMG/AMP指南分类。

主要发现

  • 36例cIgAN患者中4例携带ACMG 4/5类COL4A3杂合变异(COL4A3-cIgAN),未发现COL4A4或COL4A5变异。
  • 4例COL4A3-cIgAN儿童中3例表现为活动性IgAN的临床和生物学特征,而非Alport综合征。
  • 强化免疫抑制治疗反应良好,内皮毛细血管和毛细血管外增生病变减少。
  • 高水平的免疫球蛋白G和A(IgG/IgA)复合物、蛋白尿减少和eGFR逐渐稳定不支持Alport综合征。
  • 与非COL4A3-cIgAN组相比,COL4A3-cIgAN患者似乎更易出现更严重的IgAN表现,肾小球硬化更多且eGFR随时间下降。

临床怎么用

  • 对儿童IgA肾病患者,尤其病情较重者,可考虑COL4A3基因检测以协助评估病情严重度和治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Childhood IgA nephropathy (cIgAN) is a primary glomerulonephritis clinically characterized by microscopic hematuria and proteinuria, the presence of which may potentially overlap with Alport syndrome. Interestingly, earlier studies suggested that familial IgAN could be linked to the chromosome 2q36 region, also the coding region for collagen type 4 alpha 3/4 (COL4A3/A4). METHODS: To investigate a possible relationship or phenocopy between Alport syndrome and cIgAN, COL4A3, COL4A4, and COL4A5 exons were sequenced in 36 cIgAN patients. Clinical data and treatment were collected retrospectively. COL4A3/A4/A5 variants were classified according to American College of Medical Genetics and the Association for Molecular Pathology (ACMG/AMP) guidelines. RESULTS: Four of 36 cIgAN patients were affected by ACMG class 4/5 COL4A3 heterozygous variants (COL4A3-cIgAN). We found no COL4A4 or COL4A5 variant. Despite having rare and deleterious COL4A3 variants, 3 of 4 COL4A3-cIgAN children developed clinical and biologic features of active IgAN rather than Alport syndrome. Response to intensive immunosuppressive treatment was favorable, leading to a reduction of endocapillary and extracapillary proliferation lesions. High levels of immune immunoglobulin G and A (IgG/IgA) complexes, reduction of proteinuria, and gradual stabilization of estimated glomerular filtration rate (eGFR) argued against Alport syndrome. Nevertheless, COL4A3-cIgAN patients seemed predisposed to a more serious IgAN presentation compared with the non‒COL4A3-cIgAN group, with more glomerulosclerosis and a lower eGFR over time. One of the 4 patients underwent kidney transplant with subsequent IgAN recurrence. CONCLUSIONS: Predisposition factors for developing serious cIgAN flare-up should be considered for cIgAN with COL4A3 pathologic heterozygous variants. COL4A3 variants, usually responsible for Alport syndrome in adults, should not automatically exclude an immunosuppressive regimen in cIgAN. Moreover, evidence of an ACMG class 4/5 COL4A3 variant in early-stage cIgAN could be a helpful tool for stratifying severity of cIgAN beyond the Oxford classification.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Cambier A, Robert T, Hogan J, et al. Rare Collagenous Heterozygote Variants in Children With IgA Nephropathy. Kidney Int Rep. 2021. PMID: 34013111. doi:10.1016/j.ekir.2021.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。